FEMASYS INC
No SEC Form 4 filings for $FEMY in the last 30 days.
See all $FEMY insider activity →Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
Femasys (FEMY) announced FDA approval of its modular PMA pathway for FemBloc, a non-surgical permanent birth control. The approach allows early review of key components. FemBloc is in the FINALE trial for U.S. approval. FEMY stock rose 35.45% in premarket trading.
FEMASYS INC (FEMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update -- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory pr
Over the past 7 days, AlphAI's AI scored 1 news story mentioning FEMY (FEMASYS INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent FEMY coverage spans insider activity, regulation and corporate actions.
Strategic partnership expands distribution, modestly positive for FEMY.
Positive regulatory milestone likely to boost stock momentum.
Capital raise and regulatory/commercial milestones reduce near-term financing risk and support commercialization, but losses and low cash remain key overhangs.
A small, non-10b5-1 insider open-market buy provides mild sentiment support but is unlikely to change fundamentals on its own.
A small insider open-market buy by the CTO, with no 10b5-1 plan cited, may modestly support near-term sentiment but is unlikely to change fundamentals.
AlphAI scores every news story that mentions FEMY with an AI model for sentiment and relevance, and aggregates insider trades from FEMASYS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
3 min readFemasys (FEMY) announced FDA approval of its modular PMA pathway for FemBloc, a non-surgical permanent birth control. The approach allows early review of key components. FemBloc is in the FINALE trial for U.S. approval. FEMY stock rose 35.45% in premarket trading.
2 min readFEMASYS INC (FEMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update -- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory pr
6 min readMifek Jeffrey Gerald (Chief Clinical-Medical Affairs) purchased 3,125 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.
2 min readSipos Jeremy Alexander (Chief Technology Officer) purchased 3,125 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.
2 min readCanning John Charles (Chief Operating Officer) purchased 4,375 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.
2 min readElefant Dov (Chief Financial Officer) purchased 15,625 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.
2 min readLee-Sepsick Kathy (Chief Executive Officer) purchased 15,625 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.
1 min readFEMASYS INC (FEMY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Private Placement On August 7, 2026, Femasys Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agr
4 min readFemasys Inc. (FEMY) shares fell 11.07% to $2.65 after the company announced a $30 million private placement on Nasdaq. Femasys will sell 9.37 million shares plus pre-funded warrants and warrants for 18.75 million shares, priced at $3.20. Lead investor is Nantahala Capital, with others including Rosalind Advisors. Potential extra cash proceeds up to $60 million if warrants are exercised.
3 min read